MIM
TVTX icon

Monashee Investment Management’s Travere Therapeutics TVTX Stock Holding History

Monashee Investment Management’s Portfolio TVTX Stock Details TVTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-75,000
Closed -$1.69M – 87
2023
Q1 		$1.69M Buy
+75,000
New +$1.59M 0.47% 39
2022
Q2 		– Sell
-100,000
Closed -$2.58M – 44
2022
Q1 		$2.58M Buy
+100,000
New +$2.66M 0.75% 16
2020
Q3 		– Sell
-100,000
Closed -$2.04M – 255
2020
Q2 		$2.04M Buy
+100,000
New +$1.59M 0.31% 98
2015
Q2 		– Sell
-50,000
Closed -$1.2M – 93
2015
Q1 		$1.2M Buy
+50,000
New +$762K 0.75% 40

Other funds holding TVTX

AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
PAMS
Pictet Asset Management (Switzerland) Geneva 73, Switzerland $84.3B AUM 26.5% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Monashee Investment Management's TVTX Position: Q2 2023 in Review

Monashee Investment Management sold out of Travere Therapeutics (TVTX) in Q2 2023, closing a stake of 75,000 shares — an estimated $1.69M sold.

Monashee Investment Management first reported a position in TVTX in Q1 2015 and held it in 4 quarters. The position peaked at $2.58M in Q1 2022. 169 funds tracked by Wall St. Rank hold TVTX as of Q2 2023.

  • Monashee Investment Management reported no remaining Travere Therapeutics position as of Q2 2023 after selling out during the quarter.
  • Monashee Investment Management sold 75,000 Travere Therapeutics shares in Q2 2023, an estimated $1.69M.
  • Monashee Investment Management first reported a position in Travere Therapeutics in Q1 2015 and held it in 4 quarters.
  • Monashee Investment Management's Travere Therapeutics position peaked at $2.58M in Q1 2022.
  • 169 funds tracked by Wall St. Rank held Travere Therapeutics as of Q2 2023.

Based on Monashee Investment Management's 13F filing for Q2 2023, filed 10 Aug 2023.